An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant

Journal:

Clinical Infectious Diseases

Published:

2025-12-01

DOI:

10.1093/cid/ciaf646

Affiliations:

8

Authors:

10

Go to article

Institutions	Authors	Share
Merck & Co, United States of America (USA)	4.000000	0.40
City of Hope, United States of America (USA)	1.000000	0.10
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.10
Agostino Gemelli University Polyclinic, Italy	1.000000	0.10
University of Miami (UM), United States of America (USA)	1.000000	0.10
Manchester Royal Infirmary (MRI), MFT, United Kingdom (UK)	1.000000	0.10
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	0.500000	0.05
Weill Cornell Medicine, United States of America (USA)	0.500000	0.05

Interested in Immunology?